Your browser doesn't support javascript.
loading
A single-institution retrospective study of comprehensive genomic profiling tests based on C-CAT findings for advanced solid cancers.
Takeuchi, Susumu; Yoshimura, Akinobu; Sofuni, Atsushi; Ueda, Yuri; Umezu, Tomohiro; Kuroda, Masahiko; Sukeda, Aoi; Matsubayashi, Jun; Nagao, Toshitaka; Bingo, Masato; Inagaki, Natsuko; Ohira, Tatsuo; Seike, Masahiro; Ikeda, Norihiko.
Afiliação
  • Takeuchi S; Department of Surgery, Tokyo Medical University, Tokyo, Japan.
  • Yoshimura A; Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan.
  • Sofuni A; Department of Clinical Oncology, Tokyo Medical University Hospital, Tokyo, Japan.
  • Ueda Y; Department of Clinical Oncology, Tokyo Medical University Hospital, Tokyo, Japan.
  • Umezu T; Otorhinolaryngology, Head and Neck Surgery, Tokyo Medical University, Tokyo, Japan.
  • Kuroda M; Department of Molecular Pathology, Tokyo Medical University, Tokyo, Japan.
  • Sukeda A; Department of Molecular Pathology, Tokyo Medical University, Tokyo, Japan.
  • Matsubayashi J; Department of Anatomic Pathology, Tokyo Medical University, Tokyo, Japan.
  • Nagao T; Department of Anatomic Pathology, Tokyo Medical University, Tokyo, Japan.
  • Bingo M; Department of Anatomic Pathology, Tokyo Medical University, Tokyo, Japan.
  • Inagaki N; Clinical Genetics Center, Tokyo Medical University Hospital, Tokyo, Japan.
  • Ohira T; Clinical Genetics Center, Tokyo Medical University Hospital, Tokyo, Japan.
  • Seike M; Department of Surgery, Tokyo Medical University, Tokyo, Japan.
  • Ikeda N; Department of Pulmonary Medicine and Oncology, Graduate School of Medicine, Nippon Medical School, Tokyo, Japan.
Jpn J Clin Oncol ; 2024 Sep 19.
Article em En | MEDLINE | ID: mdl-39297618
ABSTRACT

BACKGROUND:

In recent years, as the availability of precision therapies expands, there is increasing reliance on genomic profiling assays to help identify the most appropriate treatment options for patients with advanced cancers. We retrospectively investigated the results of comprehensive genomic profiling tests from the time insurance coverage began until recently and examined the status of genetic analysis.

METHODS:

We retrospectively reviewed the analysis results of 300 patients with advanced solid tumors who consented to comprehensive genomic profiling tests from October 2019 to December 2022.

RESULTS:

Of the 300 patients who underwent comprehensive genomic profiling tests, analysis results for 274 patients were obtained, and were reviewed by the Clinical Genome Expert Panel. Six specimens (2%) were discontinued due to patient deaths and deteriorations in general condition. The three most frequently occurring actionable genomic alterations observed were TP53 (47.4%), KRAS (28.1%) and CDKN2A (20.4%). The most common druggable variant was CDKN2A, which was noted in 52 (19%) of 274 patients. The next most common were PIK3CA, BRAF, KRAS and PTEN. The cancer types that showed a greater median number of actionable alterations comprised thyroid cancer, pancreatic cancer and colorectal cancer.

CONCLUSIONS:

In conclusion, comprehensive genomic profiling tests have the potential to be valuable in identifying genomic abnormalities. Even if there is no effective treatment at present, it may lead to a treatment in the future. Comprehensive genomic profiling tests should be considered for any cancer.
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Ano de publicação: 2024 Tipo de documento: Article